Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04073147
Title Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma (VENOBI-CNS)
Acronym VENOBI-CNS
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Klinikum Stuttgart
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU


No variant requirements are available.